Compass Pathways PLC
NASDAQ:CMPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Chengdu Zhimingda Electronics Co Ltd
SSE:688636
|
CN |
|
MTI Ltd
TSE:9438
|
JP |
|
B
|
Bilibili Inc
HKEX:9626
|
CN |
|
Micro Systemation AB (publ)
STO:MSAB B
|
SE |
|
Kingswood Holdings Ltd
LSE:KWG
|
GG |
|
N
|
Nagreeka Exports Ltd
NSE:NAGREEKEXP
|
IN |
|
A
|
Aeroflex Industries Ltd
NSE:AEROFLEX
|
IN |
|
A
|
Aquarius Engines AM Ltd
TASE:AQUA
|
IL |
|
Prajay Engineers Syndicate Ltd
NSE:PRAENG
|
IN |
|
Anhui Jiuhuashan Tourism Development Co Ltd
SSE:603199
|
CN |
|
Z
|
ZJK Industrial Co Ltd
NASDAQ:ZJK
|
CN |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
|
CN |
|
Sporttotal AG
XETRA:WIG1
|
DE |
|
Zhuhai Raysharp Technology Co Ltd
SZSE:301042
|
CN |
Compass Pathways PLC
Capital Expenditures
Compass Pathways PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Capital Expenditures
-$2.4m
|
CAGR 3-Years
50%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Capital Expenditures
-£4.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Capital Expenditures
-£18.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Capital Expenditures
-£4.8m
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
|
Niox Group PLC
LSE:NIOX
|
Capital Expenditures
-£1.5m
|
CAGR 3-Years
-147%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-17%
|
|
Compass Pathways PLC
Glance View
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
